Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03373045 |
|
Recruitment Status :
Recruiting
First Posted : December 14, 2017
Last Update Posted : March 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Asthma |
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 5000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 5 Years |
| Official Title: | The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States |
| Actual Study Start Date : | February 27, 2018 |
| Estimated Primary Completion Date : | June 30, 2026 |
| Estimated Study Completion Date : | June 30, 2026 |
| Group/Cohort |
|---|
|
Cohort of US adults with severe asthma
To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
|
- Healthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period.
- Asthma treatment [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed. Longitudinal changes in asthma treatment will also be assessed.
- Treatment adherence [ Time Frame: At baseline, every 1 month, through study completion, assessed up to 7 years. ]Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization. Longitudinal changes in patient reported treatment adherence will also be assessed.
- Asthma control test (ACT) [ Time Frame: Change from baseline, every 1 month, through study completion, assessed up to 4 years. ]
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
In 2022, the ACT survey will be removed, and only the AIRQ will be solicited monthly.
- Patient-reported asthma exacerbations [ Time Frame: Change from baseline, every 1 month, through study completion, assessed up to 4 years. ]
Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.
In 2022, the asthma exacerbations survey will be removed, and only the AIRQ will be solicited monthly.
- Asthma Impairment and Risk Questionnaire (AIRQ) [ Time Frame: At baseline, every 1 month, through study completion, assessed up to 4 years ]AIRQ is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items. AIRQ scores range from 0 to 10, with lower scores representing better controlled asthma.
- Work Productivity and Activity Impairment Asthma questionnaire (WPAI-Asthma) [ Time Frame: At baseline, every 3 months, through study completion, assessed up to 7 years. ]Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma. Information will only be collected from procedures that are part of the patient's routine clinical care. WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities).
- St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]
Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact [psychosocial]) as well as total score.
Symptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity.
Impacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summarizes the impact of the disease on overall health status.
The score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status.
- Global evaluation of treatment effectiveness (GETE) [ Time Frame: At baseline, every 6 months, through study completion, assessed maximum up to 7 years. ]Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness. The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).
- Number of Participants With Adverse Events associated with corticosteroid therapy [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance.
- Relevant respiratory medical events [ Time Frame: At baseline, every 6 months, through study completion,assessed up to 7 years. ]Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.
- Respiratory comorbidities [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis [EGPA]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.
- Non-respiratory comorbidities [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.
- Events of special interest [ Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years. ]Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.
- Complete blood count with differential including blood eosinophil count. [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.
- Total immunoglobulin E (IgE) [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]To assess total IgE as a variable for asthma evaluation.
- Radiographic changes in asthma evaluation. [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings). Radiographic asthma evaluation conducted as part of routine care.
- Forced Vital Capacity (FVC) [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
- Forced Expiratory Volume in 1 second (FEV1) [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
- Fractional exhaled nitric oxide (FENO) [ Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years. ]To assess FENO as a variable for asthma evaluation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 130 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
1. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
2. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator's or sub-investigator's site.
3. 18 years of age and older. 4. Meeting at least one of the following three criteria (a, b, or c):
a. Uncontrolled asthma while receiving high-dose ICS with additional controllers.
i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS [American Thoracic Society/European Respiratory Society] guidelines):
- Poor symptom control: Asthma Control Questionnaire consistently ≥1.5, ACT <20 (or "not well controlled" by NAEPP [National Asthma Education and Prevention Program]/Global Initiative for Asthma guidelines).
- Frequent severe exacerbations: two or more bursts of systemic corticosteroids (≥3 days each) in the previous 12 months.
- Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.
- Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
ii. For the purposes of this study, high-dose ICS will be defined as
1. ICS at a cumulative dose of >500 μg fluticasone propionate equivalents daily as defined in Appendix A, or 2. Highest labeled dose of a combination of ICS/LABA. b. Current use of a Food and Drug Administration (FDA)-approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition).
c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition).
Exclusion Criteria
- Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient's behalf.
- Not fluent in English or Spanish.
- Inability to complete study follow-up or web-based PROs. If the patient does not have email or web access, minimal assistance from others to access the web-based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.
-
Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.
- Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non-interventional studies) as long as they continue to complete study follow-up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial [NCT] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373045
| Contact: AstraZeneca Clinical Study Information Center | 1-877-240-9479 | information.center@astrazeneca.com |
Show 140 study locations
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT03373045 |
| Other Study ID Numbers: |
D3250R00023 |
| First Posted: | December 14, 2017 Key Record Dates |
| Last Update Posted: | March 15, 2024 |
| Last Verified: | March 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Severe asthma Monoclonal antibody Corticosteroid Non-interventional |
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |